HIVFin: A webserver for prediction of Fusion Inhibitors against HIV
HOME    |   DRAW    SUBMIT |   ALGORITHM    |   DEVELOPERS    |   CONTACT    |   HELP   

Inhibitor Prediction

  KiDoQ (Mtb target)

  GDoQ (Mtb target)

  ABMpred (Mtb target)

  eBooster (Mtb target)

  MDRIpred (Mtb cell)

  CancerIN (Cancer)

  ntEGFR (Cancer EGFR)

  EGFRpred (Cancer EGFR)

  DiPCell (Pancreatic Cancer)

  DMKPred (Human Kinases)

  TLR4HI (Human TLR4)

  HIVFin (HIV)

Antigenic Properties

ADMET Properties

  MetaPred (Cytochrome P450)

  ToxiPred (Aqueous toxicity)

  DrugMint (Drug-like)

  QED (Oral drug-like)

  Format Conversion



A number of anti-HIV drugs have been developed but there is requirement of more novel drug molecules in order to tackle the drug resistant HIV strains. Among various anti-HIV drugs, Maraviroc and T20 inhibits virus entry process into human cells, Maraviroc is a CCR5-antagonist which block the interaction of V3 loop of HIV with CCR5 coreceptor. T20 (Enfuvirtide) is a peptide-based drug which bind to gp41 part of envelope protein and act as gp41-mediated fusion inhibitor.

Although a number of chemical compounds designed to act as fusion inhibitor but none has been approved till date. Hence, it is important to develop new chemical inhibitors against HIV and any method which could be helpful in identification of potential fusion inhibitor will be of great importance. Thus, HIVFin is such an in-silico method which can used for prediction of chemicals as potential fusion inhibitors by targeting Env-mediated entry process.